Form D · Biotechnology
Helix Therapeutics, Inc.
New Haven, CT · CIK 0001458721
Offering snapshot reported Dec 3, 2010 · SEC filing
- Reported sold
- $2.5M Offering amount: $3.5M
- Investors reported
- 2 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Nov 22, 2010 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Dec 3, 2010 | Initial | $2,500,000 | No comparison | 2 | SEC filing |
| Mar 20, 2009 | Initial | $262,500 | No comparison | Not reported | SEC filing |
| Mar 16, 2009 | Paper | Not reported | No comparison | Not reported | SEC filing |
Offering details
- Securities
- Equity, Option to acquire, Security to be acquired
- Exemptions
- 06
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-151384
Source: Form D, filed Dec 3, 2010. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Ranjit Bindra | Director |
| Joseph Catino | Director, Executive |
| Peter Glazer | Director |
| Kevin Rakin | Director, Executive |
| Timothy Shannon | Director |
| Russell Tweeddale | Director |
| Gerald Vovis | Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
25 Science Park 150 Munson Street
New Haven, CT, 06511
New Haven, CT, 06511